These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11716435)

  • 1. Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides.
    Geiger T; Hüsken D; Weiler J; Natt F; Woods-Cook KA; Hall J; Fabbro D
    Anticancer Drug Des; 2000 Dec; 15(6):423-30. PubMed ID: 11716435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 oncogene as a target for cancer therapy: An antisense approach.
    Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
    Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
    Phelps M; Darley M; Primrose JN; Blaydes JP
    Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased mdm-2 expression in a p53-independent manner blocks UV-induced cell cycle arrest and apoptosis in human osteosarcoma cells.
    Dong YB; Yang HL; Elliott MJ; McMasters KM
    Tumour Biol; 2003; 24(3):130-9. PubMed ID: 14610316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
    J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1.
    Sato N; Mizumoto K; Maehara N; Kusumoto M; Nishio S; Urashima T; Ogawa T; Tanaka M
    Anticancer Res; 2000; 20(2A):837-42. PubMed ID: 10810363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of HDM2 and VEGF co-expression in cancer cell lines: novel effect of HDM2 antisense treatment on VEGF expression.
    Narasimhan M; Rose R; Karthikeyan M; Rathinavelu A
    Life Sci; 2007 Oct; 81(17-18):1362-72. PubMed ID: 17931661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
    Zhang Z; Li M; Wang H; Agrawal S; Zhang R
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
    Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
    J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
    Chen L; Agrawal S; Zhou W; Zhang R; Chen J
    Proc Natl Acad Sci U S A; 1998 Jan; 95(1):195-200. PubMed ID: 9419352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
    Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
    Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
    Sasaki H; Sheng Y; Kotsuji F; Tsang BK
    Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.
    Jiang XH; Wong BC; Lin MC; Zhu GH; Kung HF; Jiang SH; Yang D; Lam SK
    Oncogene; 2001 Nov; 20(55):8009-18. PubMed ID: 11753684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
    Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
    Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Construction of antisense c-myc recombinant adenovirus and its anti-tumor effects on osteosarcoma cell lines MG-63 and U2OS].
    Xie XK; Yang DS; Ye ZM; Tao HM
    Ai Zheng; 2005 Mar; 24(3):292-7. PubMed ID: 15757529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
    Mu Z; Hachem P; Agrawal S; Pollack A
    Prostate; 2004 Aug; 60(3):187-96. PubMed ID: 15176048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer.
    Mullen P; McPhillips F; MacLeod K; Monia B; Smyth JF; Langdon SP
    Clin Cancer Res; 2004 Mar; 10(6):2100-8. PubMed ID: 15041731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.